At the forefront of cancer research
Directed by world leaders in predictive modeling, artificial intelligence, and genomics, Sema4’s research focuses on structuring data into validated clinical insights. Our researchers have published more than 1,000 peer-reviewed papers in the last five years on subjects including prognostic biomarkers, tumor profiling, and chemoimmunotherapy, and indications including non-small cell lung cancer, glioblastoma, and multiple myeloma. We collaborate with major health systems, research consortia, and advocacy groups and have recognized expertise in customized clinical trial development and recruitment, making us a trusted partner to pharma. Learn more about our research.
“Sema4’s expertise in data science, machine learning, and network modeling, combined with our best-in-class genomic tests and understanding of how to deploy these tests across a system, give us a critical edge in delivering precision oncology care solutions.”